Gardasil
Human papillomavirus type6 l1 protein, human papillomavirus type, 1 protein, human papillomavirus type, 1 protein, human papillomavirus type, 1 protein
The register's composition for this product is incomplete, so it is not grouped under a compound.
EACH 0,5 ml DOSE CONTAINS HUMAN PAPILLOMAVIRUS TYPE6 L1 PROTEIN 30,0 ug, HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN 40,0 ug,HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN 60,0 ug,HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN 40,0 ug,HU
Combination product
This product contains more than one active ingredient, so it has no single molecular structure.
Registration
- Applicants
- 1
- Registrations
- 1
Applicants and registrations
Variants
| Product | Strength and form | Registration | Status | Schedule | Leaflets |
|---|---|---|---|---|---|
| Gardasil 9 EACH 0,5 ml DOSE CONTAINS HUMAN PAPILLOMAVIRUS TYPE6 L1 PROTEIN 30,0 ug, HUMAN PAPILLOMAVIRUS TYPE 11 L1 PROTEIN 40,0 ug,HUMAN PAPILLOMAVIRUS TYPE 16 L1 PROTEIN 60,0 ug,HUMAN PAPILLOMAVIRUS TYPE 18 L1 PROTEIN 40,0 ug,HU | 0,5 mLInjection | 51026451/30.1/0264Approved 18 August 2025 | Registered | Not determined | PIPIL |
Regulatory status
This product is still scheduled by law even when this site could not determine which tier it falls under. The label carries the S number in a square border; ask a pharmacist if you need to know its schedule.
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.
Background
SAHPRA documents
These documents come from SAHPRA's PI-PIL repository unless the line under a document says otherwise. Always consult with a healthcare professional for medical advice.